Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transplants

PHASE2/PHASE3WithdrawnINTERVENTIONAL

Timeline

Start Date

December 31, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

October 31, 2026

Conditions

Kidney Transplant Rejection

Interventions

BIOLOGICAL

MDR-102

Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells

DRUG

Immunosuppressive Agents

Standard Anti-Rejection Medications that would be given to kidney transplant recipients who are outside the study